Background Biosynthesis of extragonadal androgen may contribute to the progression of
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of …

Background Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall
survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We …

Background Abiraterone acetate improved overall survival in metastatic castration-resistant
prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-…

Background Abiraterone acetate plus prednisone significantly improved radiographic
progression-free survival compared with placebo plus prednisone in men with chemotherapy-…

The molecular diversity of receptors in human blood vessels remains largely unexplored.
We developed a selection method in which peptides that home to specific vascular beds are …

Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified
more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data …

To evaluate the relative efficacy of cisplatin, cyclophosphamide, and Adriamycin (doxorubicin;
Adria Laboratories, Columbus, OH) (CISCA) versus methotrexate, vinblastine, Adriamycin, …

Individual cancers harbor a set of genetic aberrations that can be informative for identifying
rational therapies currently available or in clinical trials. We implemented a pilot study to …

Metastasis to bone is common in lung, kidney, breast and prostate cancers. However, prostate
cancer is unique in that bone is often the only clinically detectable site of metastasis, and …

Six patients with metastatic mixed germ‐cell tumors who had been treated successfully with
chemotherapy had recurring solitary enlarging masses. Four had enlarging pulmonary …